Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00011986 · OUTCOME

Progression-free Survival

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer · Source last updated 2019-04-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From the date of enrollment to first progression or death or last contact, if alive and progression free.

What was measured

Median duration in months of progression free survival.

Groups in this outcome

Carbo/Taxol

Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles

Carbo/Taxol/Gemcitabine

Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Gemcitabine 800 mg/m2/dIV on days 1 and 8 x 8 cycles

Carbo/Taxol/Doxil

Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Doxil 30 mg/m2 IV every other cycle on day 1 x 8 cycles

Carbo/Topotecan - Carbo/Taxol

Topotecan 1.25 mg/m2/dIV days 1-3 plus Carboplatin AUC 5 IV on day 3 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles

Carbo/Gemcitabine - Carbo/Taxol

Gemcitabine 1000 mg/m2/dIV on days 1 and 8 plus Carboplatin AUC 6 IV on day 8 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Carbo/Taxol864
Carbo/Taxol/Gemcitabine864
Carbo/Taxol/Doxil862
Carbo/Topotecan - Carbo/Taxol861
Carbo/Gemcitabine - Carbo/Taxol861

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Carbo/Taxol16.0Not reported14.917.2Not reported
Carbo/Taxol/Gemcitabine16.3Not reported15.117.7Not reported
Carbo/Taxol/Doxil16.4Not reported15.317.5Not reported
Carbo/Topotecan - Carbo/Taxol15.4Not reported14.716.3Not reported
Carbo/Gemcitabine - Carbo/Taxol15.4Not reported14.616.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        14.9
        upper Limit
        17.2
        value
        16.0
      2. group Id
        OG001
        lower Limit
        15.1
        upper Limit
        17.7
        value
        16.3
      3. group Id
        OG002
        lower Limit
        15.3
        upper Limit
        17.5
        value
        16.4
      4. group Id
        OG003
        lower Limit
        14.7
        upper Limit
        16.3
        value
        15.4
      5. group Id
        OG004
        lower Limit
        14.6
        upper Limit
        16.4
        value
        15.4
denoms
  1. counts
    1. group Id
      OG000
      value
      864
    2. group Id
      OG001
      value
      864
    3. group Id
      OG002
      value
      862
    4. group Id
      OG003
      value
      861
    5. group Id
      OG004
      value
      861
    units
    Participants
description
Median duration in months of progression free survival.
dispersion Type
95% Confidence Interval
groups
  1. description
    Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles
    id
    OG000
    title
    Carbo/Taxol
  2. description
    Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Gemcitabine 800 mg/m2/dIV on days 1 and 8 x 8 cycles
    id
    OG001
    title
    Carbo/Taxol/Gemcitabine
  3. description
    Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Doxil 30 mg/m2 IV every other cycle on day 1 x 8 cycles
    id
    OG002
    title
    Carbo/Taxol/Doxil
  4. description
    Topotecan 1.25 mg/m2/dIV days 1-3 plus Carboplatin AUC 5 IV on day 3 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles
    id
    OG003
    title
    Carbo/Topotecan - Carbo/Taxol
  5. description
    Gemcitabine 1000 mg/m2/dIV on days 1 and 8 plus Carboplatin AUC 6 IV on day 8 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles
    id
    OG004
    title
    Carbo/Gemcitabine - Carbo/Taxol
param Type
MEDIAN
reporting Status
POSTED
time Frame
From the date of enrollment to first progression or death or last contact, if alive and progression free.
title
Progression-free Survival
type
PRIMARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice